Extracellular vesicles show promise for cancer theranostics
Editorial Commentary

Extracellular vesicles show promise for cancer theranostics

Meirav Segal, Frank J. Slack

HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA, USA

Correspondence to: Frank J. Slack. HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA. Email: fslack@bidmc.harvard.edu.

Provenance: This is an invited article commissioned by Section Editor Dr. Clive R. Da Costa (Principal Laboratory Research Scientist, Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK).

Comment on: Jc Bose R, Uday Kumar S, Zeng Y, et al. Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents. ACS Nano 2018;12:10817-32.


Submitted Feb 07, 2019. Accepted for publication Mar 06, 2019.

doi: 10.21037/atm.2019.03.19


Extracellular vesicles (EVs) are naturally occurring small membrane vesicles (30–150 nm), protected by a lipid bilayer, that originate from endosomes and are formed through the fusion of the plasma membrane with multivesicular endosomes (MVEs), and subsequently exocytosed (1). The roles of EVs are numerous and could be important in cancer biology and disease (2). A recent research topic highlights extracellular vesicles addressing the processes that they regulate in cancer and their potential therapeutic value. The manuscript entitled “Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for Cancer-Specific Delivery of AntimiR-21 and Imaging Agents” published in ACSNano by Rajendran Jc Bose et al. investigated the delivery of antimiR-21 by tumor extracellular vesicles (TEV) and the attenuation of DOX resistance in breast cancer. Importantly, the authors demonstrated that TEVs may act as a biomimetic source for the activation of gold-iron oxide nanoparticles and observable nanotheranostic characteristics by TEV-gold-iron oxide nanoparticles in vitro.

To provide readers with some background context in the field of EV-mediated processes in cancer, we first present several aspects of EVs, from functions in cancer development, roles as potential biomarkers in tumor diagnosis and prognosis and potential roles as delivery vehicles in cancer tumor therapy.

EVs can be found in all cell types including dendritic cells (DCs) (3), T cells (4), B cells (5), neurons (6), and tumor cells (7-9). EVs have also been found in human biological fluids, such as blood and urine (10). Extracellular vesicles are one possible mechanism responsible for the connection between cells of the tumor & its microenvironment (11). The content of the extracellular vesicles depend on the donor cell type they derive from and consist of a plethora of molecules including RNAs [microRNAs (miRNAs) and mRNAs], proteins, signaling peptides, and lipids (12). In addition, EVs can also transfer DNA, thus modifying gene expression in recipient cells and further extending EVs interactions. Moreover, they are involved in local and systemic cell communication (13) and directional transportation of cargoes to specific locations. Different cells derive extracellular vesicles with unique cargoes, commonly miRNAs or mRNA, which may be used as molecular markers in tumor diagnosis, e.g., potential determining the specific cancer subtype.

miRNAs are small non-coding RNAs that control gene expression at a post-transcriptionally and have important functions in tumorigenesis (14). miRNAs are known to be dysregulated in many types of cancer and specific miRNA expression patterns characterize normal versus tumor tissue or differentiated versus poorly differentiated tumors. Thus, miRNAs hold putative value in cancer patient diagnostics and prognostics. Upregulated miRNAs in cancer cells promote carcinogenesis by attenuating tumor suppressor genes, and are known as oncomiRs (oncogenic miRNAs) (15). On the other hand, miRNAs with low expression levels in cancer cells that typically halt cancer progression by suppression of the expression of oncogenes, are called tumor suppressor microRNAs (16). Silencing highly expressed miRNA with anti-miRNAs (antimiRs or antagomirs) or substituting tumor suppressor miRNAs with miRNA mimetics has been demonstrated as a valuable experimental strategy for the treatment of cancer. However, delivery of miRNA-based therapeutics is challenging (17) and extracellular vesicles have been recently explored as a mechanism for RNA therapy (18).

In a recent review (19) focused on the role of TEV as a tumor therapy, the authors presented evidence implying that ncRNAs can modulate gene expression locally and systemically. In another study, after delivery of mouse exosomal RNA to human cells, different mouse proteins were seen in the recipient cells, confirming that delivery of exosomal mRNA can be translated after introduction to a different cell. This showed that exosomes consisting of mRNA and miRNA, can be transferred to another cell, and can be active in a new location.

Earlier research demonstrated that microRNA-21 (miR-21) is highly-expressed in esophageal tumors and in their TEV’s. One study analyzed the action of exosome-miR-21 association in the advancement in esophageal cancer (20). The study discovered that exosomes are absorbed from the outside of the cell into the cytoplasm. The exosomes labeled with Cy3-miR-21 mimics were delivered to new cells through a neutral sphingomyelinase 2 (nSMase2)-dependent technique. High levels of miR-21 from contributor cells dramatically improved the migration and invasion of recipient cells through targeting of programmed cell death 4 (PCDC4) and stimulating the c-Jun N-terminal kinase (JNK) pathway. In another study, a cross-comparison analysis of miRNA-21 and -10b (both have been shown to be involved in breast cancer initiation and metastasis) and mRNA expression profiles of normal cells MCF10A cells that were exposed to MDA-MB-231 cancer exosomes revealed a correlation between the up-regulated miRNA-21 and -10b and a down-regulation of their mRNA targets, PTEN and HOXD10. Moreover, immunoblots of PTEN and HOXD10 confirmed they were silenced in MCF10A cells exposed to cancer exosomes (2).

In this current manuscript by Rajendran Jc Bose et al., demonstrated a simplicity in the processing of cell derived materials and packaging of miRNAs in TEVs, and that gold-iron oxide nanoparticle activation offers a new platform for cancer therapeutics and imaging. The authors emphasise the advantages of cell-derived vesicles such as biocompatibility, minimal toxicity, safety, simplicity of construction, loading of diverse groups of agents, and crucially promotion of tissue-specific delivery. They initially investigated cellular internalization and release of intracellular Cy5-antimiRNA-21 from TEVs-Cy5-antimiRNA-21 in homologous tumor cells and then in another type of tumor cell and found that the Cy5-fluorescence signal peak gets higher with time of incubation and concentration of TEVs. This was also confirmed by measuring high levels of antimiR-21 using real-time PCR. The effect of delivered antimiR-21 was further confirmed by quantification of miR-21 downstream target gene levels—the levels of PTEN and PDCD4 were dramatically increased. Moreover, the authors showed that the simultaneous treatment with TEV antimiRNA-21 and low-dose DOX, to 4T1 tumor cells resulted in a spindle-like configuration, cell detachment and apoptotic death. This which was not observed in cells treated with TEVantimiR-21 alone nor DOX alone. In addition, the authors evaluated the use of TEV with gold-iron-oxide nanoparticles (GIONs) which act as a photosensitizer for photothermal therapy (PTT). The outcome of the activity of TEVs-antimiRNA-21 on GIONs was enhanced cytotoxicity, whilst conversely cells not treated preserved their activity. In vivo biodistribution indicated high accumulation in tumors of TEV-GION or TEVGION-antimiRNA-21 even after 12 days of repeated post-injection. AntimiRNA-21 distribution in tumors and primary organs was evaluated by real time PCR with a high level of GION-antimiRNA-21 observed in the 4T1 tumors versus different organs. Moreover, antimiRNA-21 was dramatically increased also in the liver, lung, and brain. TEVGION- antimiRNA-21 was also further tested as a diagnostic tool via MRI.

In conclusion, TEV-mediated delivery of miRNA is a promising tool for cancer theranostics. It may function as a biomarker and as delivery vehicle of anticancer drugs. However, the isolation and processing of EVs is still not consistently reproducible and further optimization is still required. Ongoing studies regarding the cargo contents of TEV are required and will help to identify relevant biomarkers and targeting residues. Exciting times are ahead of us as EVs make progress towards being successful delivery agents for cancer therapy.


Acknowledgements

Funding: The authors acknowledge NIH-YALE SPORE in Lung Cancer P50CA196530. Additional support to FJ Slack was provided by the Ludwig Center at Harvard.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Zaborowski MP, Balaj L, Lai CP, et al. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience 2015;65:783-97. [Crossref] [PubMed]
  2. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014;26:707-21. [Crossref] [PubMed]
  3. Zheng L, Li Z, Ling W, et al. Exosomes Derived from Dendritic Cells Attenuate Liver Injury by Modulating the Balance of Treg and Th17 Cells After Ischemia Reperfusion. Cell Physiol Biochem 2018;46:740-56. [Crossref] [PubMed]
  4. Ludwig S, Floros T, Theodoraki MN, et al. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res 2017;23:4843-54. [Crossref] [PubMed]
  5. Rajendran RL, Gangadaran P, Bak SS, et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. Sci Rep 2017;7:15560. [Crossref] [PubMed]
  6. Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 2011;46:409-18. [Crossref] [PubMed]
  7. Aharon A, Sabbah A, Ben-Shaul S, et al. Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function. Oncotarget 2017;8:63265-80. [Crossref] [PubMed]
  8. Baumgart S, Holters S, Ohlmann CH, et al. Exosomes of invasive urothelial carcinoma cells are characterized by a specific miRNA expression signature. Oncotarget 2017;8:58278-91. [Crossref] [PubMed]
  9. Rabe DC, Rustandy FD, Lee J, et al. Tumor extracellular vesicles are required for tumor-associated macrophage programming. bioRxiv 2018.375022.
  10. Cappello F, Logozzi M, Campanella C, et al. Exosome levels in human body fluids: A tumor marker by themselves? Eur J Pharm Sci 2017;96:93-8. [Crossref] [PubMed]
  11. Le MT, Hamar P, Guo C, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest 2014;124:5109-28. [Crossref] [PubMed]
  12. Raposo G, Stoorvogel W.. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83. [Crossref] [PubMed]
  13. Srivastava A, Filant J, Moxley KM, et al. Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment. Curr Gene Ther 2015;15:182-92. [Crossref] [PubMed]
  14. Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015;518:107-10. [Crossref] [PubMed]
  15. Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma 2013;3:17. [Crossref] [PubMed]
  16. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78. [Crossref] [PubMed]
  17. Cheng CJ, Saltzman WM, Slack FJ. Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem 2013;20:3582-93. [Crossref] [PubMed]
  18. Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 2017;546:498-503. [Crossref] [PubMed]
  19. Sun YZ, Ruan JS, Jiang ZS, et al. Extracellular Vesicles: A New Perspective in Tumor Therapy. Biomed Res Int 2018;2018:2687954. [Crossref] [PubMed]
  20. Liao J, Liu R, Shi YJ, et al. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. Int J Oncol 2016;48:2567-79. [Crossref] [PubMed]
Cite this article as: Segal M, Slack FJ. Extracellular vesicles show promise for cancer theranostics. Ann Transl Med 2019;7(7):158. doi: 10.21037/atm.2019.03.19